September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
The persistence of pain relief after corneal crosslinking in mild bullous keratopathy eyes
Author Affiliations & Notes
  • Takashi Ono
    Miyata Eye Hospital, Miyakonojo, Miyazaki, Japan
  • Yukiko Terada
    Tokyo Metropolitan Geriatric Hospital, Itabashi-ku, Tokyo, Japan
  • Yosai Mori
    Miyata Eye Hospital, Miyakonojo, Miyazaki, Japan
  • Ryohei Nejima
    Miyata Eye Hospital, Miyakonojo, Miyazaki, Japan
  • Miyuki Ogata
    Miyata Eye Hospital, Miyakonojo, Miyazaki, Japan
  • Keiichiro Minami
    Miyata Eye Hospital, Miyakonojo, Miyazaki, Japan
  • Kazunori Miyata
    Miyata Eye Hospital, Miyakonojo, Miyazaki, Japan
  • Footnotes
    Commercial Relationships   Takashi Ono, None; Yukiko Terada, None; Yosai Mori, None; Ryohei Nejima, None; Miyuki Ogata, None; Keiichiro Minami, None; Kazunori Miyata, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 2919. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Takashi Ono, Yukiko Terada, Yosai Mori, Ryohei Nejima, Miyuki Ogata, Keiichiro Minami, Kazunori Miyata; The persistence of pain relief after corneal crosslinking in mild bullous keratopathy eyes. Invest. Ophthalmol. Vis. Sci. 2016;57(12):2919.

      Download citation file:


      © 2017 Association for Research in Vision and Ophthalmology.

      ×
  • Supplements
Abstract

Purpose : Crosslinking (CXL) corneal collagen to edematous corneal stroma effectively reduces central corneal thickness and relieves pain. The prospective observational case study was to examine the persistence of pain relief of bullous keratopathy (BK) up to 1 year after CXL treatment and to observe the stroma using in vivo confocal microscopy.

Methods : Eleven eyes from 11 patients who underwent consecutive CXL treatments for BK between September 2011 and December 2013 were followed up over the course of one year. The mean patient age was 78.6 ±12.0 (SD) years. The best-corrected visual acuity (BCVA), intraocular pressure (IOP), and corneal thickness were examined before treatment, as well as 1 week and 1, 3, 6, and 12 months after treatment. The intensity and frequency of pain were scaled from 0 (minimum) to 10 (maximum). At 12 months after CXL treatment, the corneal stroma at depths of 100 and 200 μm was observed via confocal microscopy, and the densities of keratocytes (cell/mm2) and nerve fibers (mm/mm2) were calculated.

Results : The BCVA after treatment did not significantly improve from that before treatment (P=0.996, Kruskal-Wallis test). In the CCT, there was no significant change at any examination point (P=0.52). The mean pain intensity score was 6.27 (range: 0-9) before treatment and significantly decreased after treatment (P<0.01): the score at 12 months was 1.80 (range: 0-6; P<0.01). The mean pain frequency score was 5.45 (range: 0-10) before treatment and significantly decreased after treatment (P<0.05): the score at 12 months was 1.27 (range: 0-5; P<0.01). Confocal microscopy observations showed keratocytes and nerve fibers were rarely observed at 12 months after CXL. At a depth of 100 μm, the gross keratocyte and nerve fiber densities for all images were 5.1 cells/mm2 and zero, respectively. At a depth of 200 μm, the gross densities were 2.9 cells/mm2 and 0.21 mm/mm2, respectively.

Conclusions : CXL effectively relieved the intensity and frequency of BK pain for at least 1 year after treatment. In vivo confocal microscopic observation and a lack of change in CCT demonstrated that the persistence of pain relief was attributable to the inadequate regeneration of nerve fibers in the corneal stroma.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×